ArticleKorean journal of radiology2025
Pretreatment [⁶⁸Ga]-PSMA-11 PET/CT to Predict the Response to Treatment With Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Article in Korean journal of radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Response to Comments on "Pretreatment [⁶⁸Ga]-PSMA-11 PET/CT to Predict the Response to Treatment With Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma".Korean journal of radiology · 2026Article
- Comments on "Pretreatment [⁶⁸Ga]-PSMA-11 PET/CT to Predict the Response to Treatment With Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma".Korean journal of radiology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
objectiveThis study aimed to investigate the feasibility of pretreatment ⁶⁸Ga-labeled prostate-specific membrane antigen-11 ([⁶⁸Ga]-PSMA-11) PET/CT for predicting treatment response in patients with metastatic renal cell carcinoma (mRCC) undergoing first-line therapy with tyrosine kinase inhibitors (TKIs) in combination with immune checkpoint inhibitors (ICIs). MATERIALS AND
methodsThis retrospective study included 108 patients (age, 69.4 ± 6.2 years; 38 males) with mRCC who underwent pretreatment [⁶⁸Ga]-PSMA-11 PET/CT and were treated with TKIs plus ICIs between January 2019 and March 2023. Evaluation of the therapeutic response to treatment with TKIs plus ICIs was based on the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Univariable and multivariable logistic regression analyses were performed to identify the independent predictors of response, defined as complete response (CR) or partial response (PR), to combinations of TKIs and ICIs. Receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive performance.
resultsOf the 108 patients with mRCC, 12 (11.1%), 24 (22.2%), 45 (41.7%), and 27 (25.0%) achieved CR, PR, stable disease, and progressive disease, respectively. The area under the curve of the cumulative standardized uptake value (SUV)-volume histogram (AUC-CSH) (adjusted odds ratio [aOR], 8.358;
conclusionAUC-CSH and SUVmax from pretreatment [⁶⁸Ga]-PSMA-11 PET/CT scans were independent predictors of the response to treatment with TKIs plus ICIs in mRCC. When combined with PD-L1 status, they may enhance patient stratification and facilitate clinical decision-making before treatment initiation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.